MA61866B1 - Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 - Google Patents

Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2

Info

Publication number
MA61866B1
MA61866B1 MA61866A MA61866A MA61866B1 MA 61866 B1 MA61866 B1 MA 61866B1 MA 61866 A MA61866 A MA 61866A MA 61866 A MA61866 A MA 61866A MA 61866 B1 MA61866 B1 MA 61866B1
Authority
MA
Morocco
Prior art keywords
compounds
formula
inhibitors
diacylglyceride
acyltransferase
Prior art date
Application number
MA61866A
Other languages
English (en)
Inventor
Yeon-Hee Lim
Emma Helen SOUTHGATE
Jianming Bao
Eric R. Ashley
Chen CHENG
James P. ROANE
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MA61866B1 publication Critical patent/MA61866B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés de formule I et des sels, esters et promédicaments pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de DGAT2. L'invention concerne également des procédés de fabrication de composés de formule I, des compositions pharmaceutiques comprenant les composés de formule I et des procédés d'utilisation de ces composés pour traiter la stéatose hépatique, la stéatohépatite non alcoolique (NASH), la fibrose, le diabète sucré de type 2, l'obésité, l'hyperlipidémie, l'hypercholestérolémie, l'athérosclérose, le déclin cognitif, la démence, les maladies cardiorénales telles que les maladies rénales chroniques et l'insuffisance cardiaque et des maladies et affections associées, comprenant l'administration d'un composé de formule I à un patient en ayant besoin.
MA61866A 2020-10-08 2021-10-06 Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 MA61866B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089068P 2020-10-08 2020-10-08
EP21802077.4A EP4225739B1 (fr) 2020-10-08 2021-10-06 Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
PCT/US2021/053680 WO2022076495A1 (fr) 2020-10-08 2021-10-06 Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2

Publications (1)

Publication Number Publication Date
MA61866B1 true MA61866B1 (fr) 2026-02-27

Family

ID=78500729

Family Applications (1)

Application Number Title Priority Date Filing Date
MA61866A MA61866B1 (fr) 2020-10-08 2021-10-06 Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2

Country Status (26)

Country Link
US (1) US11976061B2 (fr)
EP (1) EP4225739B1 (fr)
JP (1) JP7604636B2 (fr)
KR (1) KR20230084258A (fr)
CN (1) CN116685577A (fr)
AR (1) AR123700A1 (fr)
AU (1) AU2021356589A1 (fr)
CA (1) CA3195014A1 (fr)
CL (1) CL2023000997A1 (fr)
CO (1) CO2023004365A2 (fr)
CR (1) CR20230159A (fr)
DK (1) DK4225739T3 (fr)
DO (1) DOP2023000069A (fr)
EC (1) ECSP23033936A (fr)
FI (1) FI4225739T3 (fr)
HR (1) HRP20260284T1 (fr)
IL (1) IL301791A (fr)
JO (1) JOP20230072A1 (fr)
LT (1) LT4225739T (fr)
MA (1) MA61866B1 (fr)
MX (1) MX2023003842A (fr)
PE (1) PE20240216A1 (fr)
SI (1) SI4225739T1 (fr)
TW (1) TW202229243A (fr)
WO (1) WO2022076495A1 (fr)
ZA (1) ZA202304148B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4225735A1 (fr) 2020-10-08 2023-08-16 Merck Sharp & Dohme LLC Préparation de dérivés d'oxindole servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
AR131250A1 (es) 2022-12-02 2025-02-26 Merck Sharp & Dohme Llc Preparación de derivados condensados de azol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162818A (en) 1875-05-04 Improvement in brick-kilns
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
EP1364945A4 (fr) * 2001-01-30 2005-08-31 Sumitomo Pharma Derives de benzimidazolidinone
EP1455815A4 (fr) 2001-12-19 2006-11-02 Millennium Pharm Inc Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US20080287479A1 (en) * 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
EP2174343A1 (fr) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Procédé de fabrication d'un dispositif à semi-conducteurs
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
WO2009042053A2 (fr) 2007-09-21 2009-04-02 Merck & Co., Inc. Agonistes du récepteur de la neuromédine u et leurs utilisations
KR20120109292A (ko) * 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
JP2015515472A (ja) 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
LT3119757T (lt) 2014-03-17 2018-07-10 Pfizer Inc. Diacilglicerolio aciltransferazės 2 inhibitoriai, skirti panaudoti metabolinių ir susijusių ligų gydyme
WO2016036633A1 (fr) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Dérivés de tétrahydroisoquinoléine utiles en tant qu'inhibiteurs de diacylglycéride o-acyltransférase 2
WO2016036638A1 (fr) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Dérivés d'isoquinoline utiles en tant qu'inhibiteurs de diacylglycéride o-acyltransférase 2
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
CA2991894A1 (fr) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulateurs de diacylglycerol acyltransferase 2 (dgat2)
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018093698A1 (fr) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. Dérivés d'indole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
AU2017360939B2 (en) * 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3643711A1 (fr) * 2018-10-24 2020-04-29 Bayer Animal Health GmbH Nouveaux composés anthelminthiques
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑

Also Published As

Publication number Publication date
LT4225739T (lt) 2026-03-25
AR123700A1 (es) 2023-01-04
CN116685577A (zh) 2023-09-01
CL2023000997A1 (es) 2023-10-06
PE20240216A1 (es) 2024-02-16
JP7604636B2 (ja) 2024-12-23
CO2023004365A2 (es) 2023-04-17
TW202229243A (zh) 2022-08-01
CR20230159A (es) 2023-06-02
EP4225739B1 (fr) 2026-01-21
DOP2023000069A (es) 2023-05-15
US20220112182A1 (en) 2022-04-14
SI4225739T1 (sl) 2026-03-31
EP4225739A1 (fr) 2023-08-16
HRP20260284T1 (hr) 2026-04-10
FI4225739T3 (fi) 2026-03-04
CA3195014A1 (fr) 2022-04-14
DK4225739T3 (da) 2026-02-09
JP2023545741A (ja) 2023-10-31
AU2021356589A9 (en) 2025-03-13
MX2023003842A (es) 2023-04-14
IL301791A (en) 2023-05-01
WO2022076495A1 (fr) 2022-04-14
ZA202304148B (en) 2024-11-27
ECSP23033936A (es) 2023-06-30
JOP20230072A1 (ar) 2023-04-06
KR20230084258A (ko) 2023-06-12
AU2021356589A1 (en) 2023-05-25
US11976061B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
AU706628B2 (en) Treatment of arteriosclerosis and xanthoma
FI66860B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-1-imidazolylalkyl)indolderivat
JPH09505082A (ja) Ｔｎｆ放出の阻害剤としてのイソオキサゾリン
CA3092749A1 (fr) Composes deuteres utilises en tant qu'inhibiteurs de rock
MA30412B1 (fr) Composés Pharmaceutiques
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA61866B1 (fr) Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
WO2006125180B1 (fr) Derives de piperazine: utilisation comme agents therapeutiques
AU2007341218B2 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
DOP2023000068A (es) Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2
JPH07228529A (ja) コリンエステラーゼ賦活剤
MX2024002146A (es) Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
MA31031B1 (fr) NOUVEAUX DÉRIVÉS AMINOPYRROLO[1,2-a]INDOLE ET AMINOPYRIDAZINO[1,6-a]INDOLE, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GEAP202516792A (en) Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
MX2023007626A (es) Preparacion de derivados de tetrahidroindazol como innovadores inhibidores de la diacilglicerido o-aciltransferasa 2.
US6156793A (en) Prophylactic/therapeutic agents for atherosclerosis
WO2023044315A3 (fr) Inhibiteurs de kca3.1 pour la protection des podocytes
MX2025004975A (es) Preparación de derivados de triazolopiridina como nuevos inhibidores de diacilglicérido o-aciltransferasa 2
JPH01104064A (ja) 塩基性に置換されたベンゾフランカルボン酸アミド、この化合物の製法及びこれを含有する医薬
MX2025004974A (es) Preparación de derivados de imidazopiridina e imidazopiridazina como inhibidores novedosos de la diacilglicerol u o-aciltransferasa 2
MX2025004977A (es) Preparación de derivados de pirazolopiridina y triazolopiridina como inhibidores de diacilglicérido o-aciltransferasa 2 novedosos
US9926269B2 (en) Beta-lactam cholesterol absorption inhibitors
KR101902002B1 (ko) Cetp 억제제로서의 옥사졸리딘온 유도체 화합물
MA27408A1 (fr) Nouveaux composes antimycobacteriens
WO2010099388A1 (fr) Utilisation combinée d'un inhibiteur de la pde3 et d'autres agents